• Home
  • Search by Medical Condition
  • Anticoagulation
  • DOAC - Choosing between apixaban, rivaroxaban, dabigatran & edoxaban

DOAC - Choosing between apixaban, rivaroxaban, dabigatran & edoxaban

Print

Why this page is important: No trials have directly compared different DOACs with each other, but this table will enable you to determine which DOAC is best for your patient based on the patient's characteristics. 

 

Patient characteristics Advice DOAC recommended
Previous GI Bleed / disorder Chose agent/dose with fewer reported GO efects apixaban

High risk of bleeding, e.g. HAS‐BLED >3 or elderly patient

Consider agent/dose with the lowest incidence of bleeding (non specialists ‐ consider seeking advice) edoxaban, dabigatran110mg, apixaban
High risk of ischaemic stroke, low bleeding risk Consider agent/dose with the best reduction of ischaemic stroke dabigatran 150mg
Previous stroke (secondary prevention) Consider best investigated agent or greatest reduction of secondary stroke edoxaban, rivaroxaban, apixaban
CAD, previous MI or high‐risk for ACS/MI Consider agent with a positive effect in ACS rivaroxaban
Renal impairment Consider agent least dependent on renal function edoxaban 30mg (reduced dose), rivaroxaban 15mg, apixaban
Patient non-compliance Consider once daily dosing  edoxaban, rivaroxaban
Patient uses blister packs  Dabigatran & warfarin unsuitable  rivaroxaban apixaban edoxaban

 

 https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/9_DOAC_prescribing_support.pdf

 

 

 

 

 

 

 

 

 

 

 

 

apixaban dabigatran edoxaban rivaroxaban Warfarin

© 2023 AskShilpa.com | WellBN Ltd

Press enter to search

If you are involved in the prescribing process, then AskShilpa has been created for you!

01273 772020
contact@askshilpa.com
18-19 Western Rd, Hove BN3 1AE

Shilpa's Words

We love askshilpa.com